Full-Time

Cardiovascular Disease Specialist

Posted on 8/21/2026

Deadline 9/4/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$79.2k - $167.2k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

North Wales, PA, USA

Remote

The role covers a Greensboro-area North Carolina territory, requires about 25% overnight travel, and may require relocation at the candidate’s expense if outside the territory distance limit.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Lead Generation
CRM
Customer Service
Data Analysis

Get referred to Merck

See people who can refer or advise you

Requirements
  • A bachelor's degree (BA/BS), or a high school diploma or equivalent with 0–3 years of relevant work experience for S1.
  • A bachelor's degree (BA/BS), or a high school diploma or equivalent with 3 or more years of sales experience, or a high school diploma with at least 6 years of relevant work experience for S2.
  • Ability to analyze complex data and leverage insights to develop strategic sales plans.
  • Comfort using digital tools and platforms to engage with healthcare professionals.
  • Flexibility and adaptability to changing market conditions and customer expectations.
  • A demonstrated record of success in educational and professional environments, with strong interpersonal, analytical, and communication skills.
  • Ability to work independently and collaboratively, with strong organizational and time-management skills.
  • A valid driver's license.
  • Strong ability to build and maintain customer relationships by understanding and addressing customer needs.
  • Residence within the territory or within 25 miles of the workload center for designated metro territories, or within 75 miles for non-metro territories; candidates outside these distances must relocate at their own expense.
Responsibilities
  • Develop and execute a territory-level business plan in alignment with company policies, standards, and ethics.
  • Maintain current product knowledge and certifications for the company’s portfolio.
  • Conduct balanced and compliant product sales discussions with healthcare providers and business professionals according to product labeling.
  • Provide management with regular updates on customer needs, marketplace dynamics, and progress toward quality goals.
  • Maintain knowledge of headquarters-approved information regarding approved company products, disease, and the marketplace.
  • Monitor business performance against objectives using company tools to support effective planning and sales impact.
  • Develop and manage relationships with cardiologists, primary care providers, and other healthcare professionals across physicians’ offices, integrated delivery systems, pharmacies, and hospital clinics.
Desired Qualifications
  • Background in sales, account management, consultative roles, or customer service.
  • Experience analyzing metrics to evaluate progress toward goals.
  • A minimum of 3 years of relevant sales experience.
  • Cardiovascular sales experience with established relationships with cardiologists and endocrinologists.
  • Experience launching products and succeeding in competitive markets.
  • Ability to simplify complex information and clearly convey technical details.
  • Proficiency in using advanced analytics to generate customer insights and drive sales.
  • Comfort leveraging multichannel tools and technology to expand sales reach and impact.
  • A proactive learning approach and agile growth mindset.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.6 billion; management raised full-year guidance to $66.3-$67.3 billion.
  • Keytruda QLEX generated $463 million in Q2 2026, cushioning future intravenous Keytruda erosion.
  • SCRI partnership broadens oncology trial access across 200 community sites, accelerating enrollment.

What critics are saying

  • Gardasil weakness triggered 150 North Carolina layoffs in February 2026 and continues pressuring vaccines.
  • The Terns deal created a $5.7 billion charge, crushing 2026 adjusted EPS to $2.66-$2.76.
  • Keytruda still dominates sales; a 2028-2029 patent cliff would hit Merck's core franchise.

What makes Merck unique

  • Keytruda family produced $8.4 billion in Q2 2026 across earlier- and metastatic cancers.
  • Merck stacked first-in-class perioperative bladder, kidney, and melanoma approvals during July-August 2026.
  • Animal Health adds durable diversification, with INNOVAX ND-IBD-ILT USDA approval August 13, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

Yahoo Finance
Aug 20th, 2026
Merck melanoma vaccine trial beats expectations, but RBC downgrades stock over $30B Keytruda patent cliff

Merck's promising Phase 3 melanoma trial results drew mixed reactions from Wall Street. RBC Capital downgraded Merck to 'Sector Perform' from 'Outperform', calling the stock's $150 valuation "unprecedented" for a company facing major patent expiry in two years. Key patents covering Keytruda, Merck's best-selling cancer drug that generated over $30 billion in 2025 and represents nearly half of its revenue, begin expiring in 2028. RBC said further gains would require the pipeline to exceed already elevated expectations. However, BofA maintained its 'Buy' rating, raising its price target to $166, citing confidence that Merck can offset Keytruda's patent challenges. BMO Capital raised its target to $170, noting the trial could represent $5.6 billion in potential peak revenue. The trial tested Intismeran Autogene with Keytruda in melanoma patients, significantly extending time without recurrence.

Yahoo Finance
Aug 20th, 2026
Moderna stock rockets 177% as mRNA cancer vaccine trial succeeds, Musk calls technology 'tremendous promise

Elon Musk endorsed mRNA technology on Wednesday, describing it as having "tremendous promise" and likening disease treatment to a "software problem" through artificial RNA. His comments followed a major cancer vaccine breakthrough by Moderna and Merck. The companies announced positive Phase 3 results for an individualised mRNA cancer vaccine — the first successful late-stage trial of its kind. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. Musk was responding to scientist Eric Topol, who highlighted the trial's success alongside progress in personalised mRNA vaccines for pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. Moderna shares surged 177%, whilst BioNTech gained 21.96% and Arcturus Therapeutics rose 25.21%. Musk has previously promoted AI and synthetic RNA as paths to transforming healthcare.